TMB-H	Head and Neck Cancer	TMB-H	Head and Neck Cancer	Immunotherapy Sensitive: C3 – Early Trials JCO Precis Oncol - 1 week (New C3) Immunotherapy Sensitive : C3 JCO Precis Oncol - 1wk	Immunotherapy Sensitive: C3 – Early Trials JCO Precis Oncol - 1 week Immunotherapy Sensitive : C3 JCO Precis Oncol - 1 week - (New C3)
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Salivary Gland Cancer	HER-2 positive	Salivary Gland Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Head and Neck Cancer	No biomarker	Head and Neck Cancer	cetuximab sarotalocan Sensitive: A1 - Approval cetuximab sarotalocan Sensitive : A1	cetuximab sarotalocan Sensitive: A1 - Approval cetuximab sarotalocan Sensitive : A1
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	toripalimab Sensitive: A1 - Approval toripalimab Sensitive : A1	toripalimab Sensitive: A1 - Approval toripalimab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	TPF Sensitive: A2 - Guideline TPF Sensitive : A2	TPF Sensitive: A2 - Guideline TPF Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Oral Cancer	PD-L1 expression	Oral Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + docetaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + docetaxel + 5-fluorouracil Sensitive : A2	cisplatin + docetaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + docetaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2

Head and Neck Cancer

Associations(559)

Associations
(559)